RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma.
Acta Pharm Sin B
; 10(6): 1004-1019, 2020 Jun.
Article
en En
| MEDLINE
| ID: mdl-32642408
4EBP-1, E binding protein-1; AKT; AKT, protein kinase B (PKB); ESCC, esophageal squamous cell carcinoma; Esophageal squamous cell carcinoma; FDA, U.S. Food and Drug Administration; H&E staining, hematoxylin and eosin staining; IC50, half maximal inhibitory concentration; PI3K, phosphatidylinositol 3 kinase; RAD001; RICTOR; RICTOR, rapamycin-insensitive companion of mTOR; TNM, tumor-node-metastasis; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; p70S6K, p70 ribosomal S6 kinase-1; pp242; rapalogs, rapamycin and its analogs
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Acta Pharm Sin B
Año:
2020
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
Países Bajos